OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
ZLDAF
Zelira Therapeutics Ltd.
0.21
0.00
0.00%
0.1814 / 0.2389 (5000 x 2500)
Zelira Therapeutics Ltd.
Level 3, 101 St Georges Terrace
Perth, WA 6000
Australia
Level 3, 101 St Georges Terrace
Perth, WA 6000
Australia
With over 10 years in corporate pharmaceutical business development, strategy & operational leadership including alliance management, Dr. Odumosu brings a unique combination of experiences from several academic, public health and life science organizations. In his recent role as Ilera Healthcare's first Chief Operating Officer, Dr Odumosu led the design, implementation and management of Ilera's business operation's post license award in 2017 through successful, market entry, product commercialization to profitability in 2018. He was also responsible for oversight and management of day to day operation of Ilera's vertically integrated grow/processor, wholesale and dispensary. In the same capacity, He led the formulation of Ilera proprietary cannabinoid-based product generating record breaking revenue projected to be $43MM in 2019. His transition to Chief Scientific Officer/EVP Pharmaceutical Division resulted in a series of product development partnerships and the successful expansion of Ilera Healthcare to Ilera Therapeutics. He continues to lead Ilera's Therapeutics efforts as a cannabinoid science company to develop cannabinoid based and clinically validated products and technologies through strategic partnerships across the global cannabis and biotechnology space.
Mr. Tim Slate has a Bachelor of Commerce from the University of Western Australia, is a Chartered Accountant, is an Associate Member of the Governance Institute of Australia and is a Graduate of the Australian Institute of Company Directors. Mr. Slate provides accounting and secretarial advice to private and public companies. Mr Slate has 15 years' experience in chartered accounting.
Osagie Imasogie has over 30 years of experience in the field of law, finance, business management, healthcare and the pharmaceutical industry. He is a co-founder and the Senior Managing Partner of PIPV Capital, a Private Equity Firm that is focused on the Life Sciences vertical. Prior to co-founding PIPV Capital, Osagie conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President. Mr. Imasogie is a serial entrepreneur and investor. He serves as Chairman and Founder of Ilera Healthcare and was also the Founder and Chairman of iCeutica, Inc., Churchill Pharma, Ception Therapeutics Inc. and Trigenesis Therapeutics Inc. In addition, he serves on the Board of a number of financial institutions such as FS-KKR (NYSE: FSK), Haverford Trust and StoneRidge Investments. Mr. Imasogie is a Trustee of the University of Pennsylvania, a member of the Executive Committee and Chairman of the Budget & Finance Committee of the University. In addition, Osagie a member of the Board of Overseers of the University of Pennsylvania Law School, where he is an Adjunct Professor of Law. Osagie also serves on the Executive Committees of the Board of the Philadelphia Orchestra and the Philadelphia Museum of Art. Osagie holds post-graduate degrees from the University of Pennsylvania Law School and the London School of Economics.
Mr. Tim Slate has a Bachelor of Commerce from the University of Western Australia, is a Chartered Accountant, is an Associate Member of the Governance Institute of Australia and is a Graduate of the Australian Institute of Company Directors. Mr. Slate provides accounting and secretarial advice to private and public companies. Mr Slate has 15 years' experience in chartered accounting.
Dr. O'Donnell served as Special Assistant to the President, Dr. Stephen K Klasko, and is Senior Vice President for Innovation Partnerships and Programs at Thomas Jefferson University. Donna has led a diverse and successful career in health care, life sciences and public service concentrated in the Greater Philadelphia area. Donna was formerly a principal with O'Donnell Associates, her clients included non-profit organizations, universities, and life science companies, including Cephalon Pharmaceuticals. She was previously the managing director of the Eastern Technology Council for nine years. There, she played a significant role in developing and creating BioAdvance, a state entity designed to grow the life sciences industry in Southeastern Pennsylvania, as well as many other key life science initiatives. She was a special limited partner in PA Early Stage Partners.
None
Level 40
2 Park Street
Sydney, NSW 2000
Australia
801 Brickell Avenue,
8th Floor
Miami, FL 33131
801 Brickell Avenue,
8th Floor
Miami, FL 33131
Level 4, The Read Buildings,
16 Milligan Street
Perth, WA 6000
Australia
Zelira has established a special purpose vehicle (SPV) to conduct FDA Phase 1, Phase 2 and Phase 3 clinical trials for Zelira’s proprietary and patent protected HOPE® 1. Zelira has contributed to the SPV its HOPE® 1 product, IP and real-world data for 55% equity ownership of the SPV. Cash investors will contribute a total of circa US$35 million to fund the SPV and US FDA trials for HOPE® 1 in exchange for a cumulative equity interest of 45% of the SPV. Zelira will manage the SPV as part of its business platform. The SPV has appointed iNGENū CRO Pty Ltd (iNGENū) as its Contract Research Organisation (CRO) to lead the clinical validation and regulatory registration of the study product with the US FDA through the submission of an Investigative New Drug (IND) application. In May 2023, Zelira completed an IRB approved strategically designed multi-arm, head-to-head study targeting diabetic nerve pain. The clinical trial included a comprehensive comparison against the widely recognised and highly successful multibillion dollar revenue generating drug Lyrica® (Pregabalin). Zelira has developed Enhanced Distillate Capture and Dissolution Matrix (EDCDM) technology under the brand name Zyraydi™, that solves the problem of non-uniformity and separation of cannabinoid from powder bed, opening new ways to develop pharmaceutical grade solid oral dosage forms such as capsules and tablets. Zelira will be assessing opportunities for commercialisation of this technology.
Lease offices in both Perth and Plymouth Meeting. Our office in Plymouth Meeting also has a development lab with high tech lab equipment we use to conduct various experiments. All offices are in good condition, have lease agreements with both, and thus no ownership stake.
© 2025 OTC Markets Group Inc.
Terms of ServiceLinking TermsTrademarksPrivacy StatementCode of ConductRisk WarningSupported Browsers